13 Results for "

RPMI8226

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "RPMI8226" in MCE Product Catalog:

78
78 Cited Publications
Cat. No.: HY-10455
CAS No.: 868540-17-4
Purity:  99.95%
Synonyms: PR-171
Research Areas:  

Cancer

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-104040
CAS No.: 1338934-59-0
Purity:  99.95%
Synonyms: Orin1001
Target:  

IRE1

Research Areas:  

Cancer

MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC50 of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC50 of 0.52 μM and unstresses RPMI 8226 cells with an IC50 of 0.14 μM . MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth .
loading...
    loading...
Cat. No.: HY-164099
CAS No.: 2982787-50-6
Research Areas:  

Cancer

LSD1/HDAC6-IN-2 (JBI-802) is an orally active LSD1/HDAC6/MAO-A inhibitor, with IC50 values of 5 nM, 11 nM, and 5 nM, respectively. LSD1/HDAC6-IN-2 can inhibit the growth of multiple myeloma cells MM.1S, MM.1R, and RPMI-8226. LSD1/HDAC6-IN-2 can be used for research on diseases such as acute myeloid leukemia and lymphoma .
loading...
    loading...
Cat. No.: HY-145564
CAS No.: 765914-60-1
Purity:  99.04%
Synonyms: PF-07265803; ARRY-797; ARRY-371797
Target:  

p38 MAPK

Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain .
loading...
    loading...
Cat. No.: HY-10455R
CAS No.: 868540-17-4
Synonyms: PR-171 (Standard)
Research Areas:  

Cancer

Carfilzomib (Standard) is the analytical standard of Carfilzomib. This product is intended for research and analytical applications. Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.
loading...
    loading...
Cat. No.: HY-10455S
CAS No.: 1537187-53-3
Purity:  98.73%
Carfilzomib-d8 is deuterium labeled Carfilzomib. Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.
loading...
    loading...
Cat. No.: HY-174984
CAS No.: 3098437-66-9
Target:  

p97 Caspase p62

Research Areas:  

Cancer

VCP/p97 IN-3 is a VCP/p97 allosteric inhibitor. VCP/p97 IN-3 shows the inhibitory activity against the VCP proteins with an IC50 of 9 nM and the mutant VCP proteins with IC50 of 12 nM (N660K) and 19 nM (V474A/D649A). VCP/p97 IN-3 increases K48-linked ubiquitination and the level of cleaved caspase-3. VCP/p97 IN-3 activates ER-stress and the UPR. VCP/p97 IN-3 inhibits tumor growth in RPMI-8226 cell subcutaneous xenograft mouse models. VCP/p97 IN-3 can be used for the study of multiple myeloma .
loading...
    loading...
Cat. No.: HY-177768
CAS No.: 3055552-13-8
Target:  

HDAC Apoptosis

Research Areas:  

Cancer

HDAC-IN-96 (Compound 3f) is a selective HDAC1/2 inhibitor with IC50 values of 457.1 and 433.7 nM. HDAC-IN-96 has strong inhibitory activity against multiple hematological tumor cells (RS4;11, K562, RPMI-8226, U266), with IC50 values ranging from 2.11 to 5.35 μM. HDAC-IN-96 can induce cancer cells apoptosis and S phase arrest. HDAC-IN-96 can be used for the research of cancer, such as acute lymphoblastic leukemia .
loading...
    loading...
Cat. No.: HY-149832
Target:  

Proteasome

Research Areas:  

Cancer

Anticancer agent 114 is a potent and orally active dipeptide boronic acid ester proteasome inhibitor with an IC50 value of 2.2 nM. Anticancer agent 114 has antiproliferative activity against the RPMI-8226 cells. Anticancer agent 114 can be used in research of multiple myeloma .
loading...
    loading...
Cat. No.: HY-144369
CAS No.: 3033388-83-6
Target:  

Proteasome

Research Areas:  

Cancer

Proteasome-IN-4 is an excellent and non-covalent proteasome inhibitor (IC50=8.39 nM). Proteasome-IN-4 has potent antiproliferative activities against RPMI-8226, MM-1S and MV-4-11 cell lines. Proteasome-IN-4 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-P991462

Target:  

CD38

Research Areas:  

Cancer

GBR-1342 is a human bispecific antibody (bsAb) targeting CD38 & CD3. GBR-1342 inhibits the activity of Daudi, RAJI, RPMI8226, IM-9, and NCI-H929 cancer cell lines. GBR-1342 can be used in myeloma research .
loading...
    loading...
Cat. No.: HY-168338
Research Areas:  

Cancer

CB2 receptor agonist 8 (Compound 17) is an agonist for cannabinoid receptor 2 (CB2 receptor). CB2 receptor agonist 8 exhibits cytotoxicity in cells U87, RPMI 8226, HL-60, and L929 with IC50s of 91.03, 16.29, 23.51 and 564.6 μM, respectively. CB2 receptor agonist 8 activates caspase 3/7, increases the expressions of pro-apoptotic genes BAX, BAD, BIM and tumor suppressor genes p53, and induces apoptosis in U87. CB2 receptor agonist 8 inhibits the migration of U87 .
loading...
    loading...
Cat. No.: HY-104040R
CAS No.: 1338934-59-0
Synonyms: Orin1001 (Standard)
Research Areas:  

Cancer

MKC8866 (Standard) is the analytical standard of MKC8866 (HY-104040). This product is intended for research and analytical applications. MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC50 of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC50 of 0.52 μM and unstresses RPMI 8226 cells with an IC50 of 0.14 μM . MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth .
loading...
    loading...
  • 1